Primary hemophagocytic lymphohistiocytosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Primary hemophagocytic lymphohistiocytosis.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Primary hemophagocytic lymphohistiocytosis.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

GAMIFANT

(EMAPALUMAB-LZSG)standard

Swedish Orphan Biovitrum AB (publ)

Interferon gamma Blocker [EPC]

12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Primary hemophagocytic lymphohistiocytosis.
Search all trials →
Search clinical trials for Primary hemophagocytic lymphohistiocytosis

Recent News & Research

1 article
BREAKINGFDA

FDA Approves GAMIFANT

GAMIFANT (EMAPALUMAB-LZSG) received FDA approval.

Read ↗

Browse all Primary hemophagocytic lymphohistiocytosis news →

Specialist Network

Top 6 by expertise

View all Primary hemophagocytic lymphohistiocytosis specialists →

Quick Actions